Bolt Biotherapeutics rugi bersih Q2 FY26 menyempit 9,82% menjadi USD 7,72 juta

Reuters2026/08/11 20:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bolt Biotherapeutics membukukan rugi bersih USD 7,72 juta pada kuartal II 2026, menyempit dari rugi USD 8,56 juta setahun sebelumnya.
Rugi operasional turun menjadi USD 8,37 juta dari USD 9,21 juta, sementara revenue merosot menjadi USD 5.000 dari USD 1,8 juta.
Beban R&D turun 31,33% menjadi USD 5,15 juta, dipicu penurunan biaya gaji terkait restrukturisasi serta aktivitas riset lebih rendah.
Beban G&A anjlok 31,12% menjadi USD 2,42 juta, terutama pada gaji terkait restrukturisasi serta biaya konsultansi lebih rendah.
Kas, setara kas, dan sekuritas yang dapat dipasarkan berjumlah USD 18,1 juta per 30 Juni 2026, diproyeksikan mendanai operasi hingga kuartal I 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111605PRIMZONEFULLFEED9807992) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bolt Biotherapeutics rugi bersih Q2 FY26 menyempit 9,82% menjadi USD 7,72 juta

You may also like

Crypto prices